GTx: A Compelling Biotech
GTx (GTXI; recent price, $12) is an emerging biotech with potentially significant near-term catalysts for its stock price, in Standard & Poor's view. The company expects data from two phase III studies for its lead drug candidate, Acapodene, during the first quarter of 2008. The first study, for the treatment of side effects in prostate cancer patients undergoing androgen-deprivation therapy (ADT), has produced positive interim data in secondary endpoints of improved bone mineral density and lipid control, lowering serum low-density lipoproteins, or LDLs, ("bad" cholesterol) and triglycerides. The second study, expecting interim data, is exploring Acapodene's ability to prevent prostate cancer in patients with precancerous lesions called high-grade PIN (prostatic intraepithelial neoplasia). We believe both target markets represent population opportunities of more than 1 million patients.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.